CRISPR: Move Beyond Differences
By Charis Thompson,
Nature
| 06. 24. 2015
Untitled Document
This autumn, researchers and other experts will come together to discuss the scientific, ethical and policy issues associated with gene-editing research in humans. Plans for the international meeting were announced by the US National Academy of Sciences and the National Academy of Medicine after a study was published in which researchers used a gene-editing tool known as CRISPR to modify the genomes of non-viable human embryos1.
Whether this meeting and others like it, planned in the United States, can help to forge a path for gene editing that takes into account all the relevant needs and concerns will depend on what efforts are made to integrate the diverse perspectives of people with different expertise and values. A first step to such integration is understanding how different perspectives arise.
One division in cares and concerns seems at times to fall along stereotypical gender lines. This was powerfully demonstrated during a meeting in Atlanta, Georgia, last month on biotechnology and ethics. About 200 global thought leaders gathered at BEINGS 2015 to “reach consensus on the direction of biotechnology...
Related Articles
By David Jensen, The California Stem Cell Report | 03.26.2026
SACRAMENTO, Ca. -- California’s $12 billion stem cell and gene therapy program scored a historic first today, announcing that it had for the first time helped to finance a revolutionary treatment that will now be available to the general public...
Cathy Tie seems to be good at starting businesses but not so dedicated to maintaining them. CGS, like many others, first heard of her thanks to Caiwei Chen and Antonio Regalado in MIT Technology Review, May 2025, as the partner (perhaps bride) of the notorious Chinese scientist He Jiankui, described in the headline as “China’s Frankenstein.” He prefers “Chinese Darwin.” She ran his Twitter account for a while, contributing such gems as:
Get in luddite, we’re going gene editing...
By Laura DeFrancesco, Nature Biotechnology | 03.17.2026
The first gene editors designed to fix genetic lesions in mutation-agnostic ways are poised to enter the clinic. Tessera Therapeutics and Alltrna, two Flagship Pioneering-funded companies, are gearing up to test novel genetic medicines in humans. Tessera received regulatory clearance...
By Darren Incorvaia, Fierce Biotech | 03.11.2026
A new method for safely inserting large chunks of DNA into genomes has now measured up in mice, potentially paving the way for the next generation of gene editing medicines.
The approach, which is described in a Nature paper...